Literature DB >> 32856142

Management of myelofibrosis and concomitant advanced cutaneous squamous cell carcinoma with ruxolitinib associated with cemiplimab.

Alessio Di Prima1, Andrea Botticelli2, Emilia Scalzulli1, Gioia Colafigli1, Sara Pepe1, Chiara Lisi1, Paolo Marchetti2, Maurizio Martelli1, Robin Foà1, Massimo Breccia3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32856142     DOI： 10.1007/s00277-020-04236-7

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   3.673


× No keyword cloud information.
  3 in total

1.  Aggressive Skin Cancers Occurring in Patients Treated With the Janus Kinase Inhibitor Ruxolitinib.

Authors:  Adam B Blechman; Christine E Cabell; Christine H Weinberger; Anna Duckworth; Justin J Leitenberger; Fiona O Zwald; Mark A Russell
Journal:  J Drugs Dermatol       Date:  2017-05-01       Impact factor: 2.114

Review 2.  A Review of the Global Guidelines on Surgical Margins for Nonmelanoma Skin Cancers.

Authors:  Amanda F Nahhas; Chase A Scarbrough; Shannon Trotter
Journal:  J Clin Aesthet Dermatol       Date:  2017-04

3.  Multiple squamous cell carcinomas of the skin during long-term treatment with hydroxyurea.

Authors:  C De Simone; C Guerriero; B Guidi; M Rotoli; A Venier; R Tartaglione
Journal:  Eur J Dermatol       Date:  1998-03       Impact factor: 3.328
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.